Eris Biotech
Eris Biotech is making small-molecule pills that release the brakes on the immune system inside tumours, starting with mesothelioma.
Overview
Eris Biotech develops small molecules that inhibit immune suppression in the tumour microenvironment so that the patient's immune system attacks solid tumours more aggressively, an oral alternative to antibody checkpoint inhibitors. Its first indication is mesothelioma, with a portfolio the company says extends to a range of solid tumours. The Utah company is preclinical with a very small team; no sourced financing rounds are recorded.
Funding
All startupsPages like this
not linked directly; found by shared links- CompanyPersephone Biosciences
Shares Y Combinator, Immune checkpoint inhibitors and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyLiyfe
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyREPROSENT
Shares Y Combinator and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator and the tag yc.
- CompanyDelee
Shares Y Combinator and the tag yc.